期刊文献+

四川凉山静脉吸毒人群HIV感染者中HLA-B*5701阳性率的研究 被引量:4

Prevalence of human leukocyte antigen B site 5701 allele(HLA-B*5701)in HIV infected intravenous drug users(IDUs) in Liangshan of Sichuan province
原文传递
导出
摘要 目的了解四川凉山彝族自治州静脉吸毒人群(IDUs)艾滋病病毒(HIV)感染者中,人白细胞抗原I类基因B座位5701等位基因(HLA-B*5701)的阳性率,并与国内外其他民族的研究数据进行比较。方法采用序列特异性引物(SSP)对基因组DNA进行聚合酶链式(PCR)扩增,通过琼脂糖凝胶电泳读取结果,电泳条带呈HLA-B*5701阳性的再通过测序进行HLA-B分型验证。结果 1 043名HIV阳性感染者中,5人携带HLA-B*5701等位基因,阳性率为0.479%。其中汉族人口230人,3例携带HLA-B*5701等位基因(阳性率1.30%);彝族人口813人,2例携带HLA-B*5701等位基因(阳性率0.246%)。结论凉山IDUs人群HIV感染者中HLA-B*5701的阳性率较低,低于国外对黑种人及白种人的研究数据,汉族人群与彝族人群相比较差异无统计学意义。 Objective To study the prevalence of HLA-B* 5701 in HIV infected intravenous drug users (IDUs) in Liangsha of Sichuan province in comparison with data of domestic and foreign researchers. Methods HLA-B* 5701 screening was performed using multiplexed sequence specific primers PCR(SSP-PCR) method. The results were read by agarose gel electrophoresis, with additional DNA sequencing for IDUs whose agarose gel electrophoresis findings were positive. Results Of the 1 043 HIV positive IDUs 5 carried HLA-B* 5701 allele, with a prevalence rate of 0. 479 %. Of the 230 IDUs of Han ethnic , 3 carried HLA-B* 5701 allele (1.30%) ; of the 813 IDUs of Yi ethnic 2 carried HLA-B* 5701 allele (0. 246%). Conclusion The prevalence of HLAB* 5701 in HIV infected IDUs in Liangshan was lower than that in the black and white people as identified by foreign researchers, and there was no significant difference between Han and Yi populations in this study.
出处 《中国艾滋病性病》 CAS 2011年第4期404-406,438,共4页 Chinese Journal of Aids & STD
基金 国家科技重大专项(2008ZX10001-003)~~
  • 相关文献

参考文献14

  • 1Phillips E, Mallal S. Drug hypersensitivity in HIV[J]. Current Opin ion in Allergy and Clinical Immunology 2007, 7: 324-330.
  • 2Hughes AR, et al. Genetic association studies to detect adverse drug re- actions: abacavir hypersensitivity as an example[J]. Pharmacogenom- ics, 2009,10(2): 225-233.
  • 3Hetherington S, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir[J]. Clin Ther, 2001, 23(10) : 1603- 1614.
  • 4Cutrell AG, et al. Updated clinical risk factor analysis of suspected hy persensitivity reactions to abacavir[J]. Ann Pharmacother, 2004,38 (12):2171-2172.
  • 5Martin AM, et al. Predisposition to abacavir hypersensitivity con- ferred by HLA-B * 5701 and a haplotypic Hsp70-Hom variant[J]. Proc Natl Acad Sci USA, 2004,101(12):4180-4185.
  • 6Reeves I, Churchill D, Fisher M. Screening for HLA-B * 5701 re- duces the frequency of abacavir hypersensitivity reactions[A]. In: Program and Abstracts of the Eighth International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV[C]. San Fran- cisco, CA, USA, 2006. Abstract 14. 270. Antivir Ther 2006; 11 (Suppl3) : S1-S192.
  • 7Young B, et al. First large, multicenter, open-label study utilizing HLA-B * 5701 screening for abacavir hypersensitivity in North A- merica[J]. AIDS, 2008, 22(13) : 1673- 1675.
  • 8Mallal S, Phillips E, Carosi G, et al, or the PREDICT-1 Study Team. HLA-B * 5701 screening for hypersensitivity to abacavir [J]. N Engl J Med, 2008,358:568-579.
  • 9FDA发布阿巴卡韦及含阿巴卡韦药物的安全信息.慧聪制药工业网http://info.pharmacy.hc360.com/2009/10/09154691677.shtml.2009/10/9/15:46.
  • 10Nolan D. HLA B * 5701 screening prior to abacavir prescription: clinical and laboratory aspects[J]. Crit Rev Clin Lab Sci, 2009, 46(3) :153-165.

同被引文献64

  • 1MING-YANXU,KUN-XUEHONG,XIAO-LINGDENG,JUNLI,HONGPENG,Yu-HuARUAN,GUAN-MINGQIN,HUIXING,XIAO-HUXU,ANDYI-MINGSHAO.Association of HLA-B Alleles With Human Immunodeficiency Virus Type 1 Infection in the Yi Ethnic Group in Sichuan Province[J].Biomedical and Environmental Sciences,2004,17(2):203-208. 被引量:8
  • 2袁方,孙玉英,骆媛,梁飞,刘楠,金荔,刘金锋,刘曙光,奚永志.我国汉族人群HLAⅠ类经典基因单倍型及连锁分析[J].中国实验血液学杂志,2007,15(5):1084-1089. 被引量:11
  • 3Harrigan PR, Stone C, Griffin P, et al. Resistance profile of the HIV type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy[J]. JID, 2000, 181 (3) :912-920.
  • 4Harris M, Back D, Kewn S, et al. Intracellular carbovir triphosphate levels in patients taking abacavir once a day[J]. AIDS, 21302, 16(8) :1196-1197.
  • 5Sharer R. Genotypic testing for HIV-1 drug resistance (2003). http://hivdb.stanford. edu/modules/lookUpFiles/pdf/Genotypic Resistance. pdf.
  • 6Sivasubramanian G, Frempong-Manso E, Macarthur RD. Abacavir/lamivudine combination in the treatment of HIV: A review [J]. Ther Clin Risk Manag, 2010,6(3):83-94.
  • 7EPZICOMTM (abacavir sulfate and lamivudine) tablets [product information]. Research triangle Park, North Carolina: Glaxo-Smith Kline, March 2006.
  • 8Dejesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infeeted adults[J]. Cin Infect Dis, 2004, 39(7):1038-1046.
  • 9Tan DH, Chan K, Raboud J, et al. CANOC Collaboration: Corn parison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy[J]. J Acquir Immune Defic Syndr, 2011,58(1) :38-46.
  • 10Sax P, Tierney C, Collier A, et al. ACTG 5202: Shorter time to virologic failure with ABC/3TC than tenofovir/FTC in treatment-naive subjects with HIV RNA OK 100 000[C]. 17th International AIDS Conference, Aug. 3-8, 2008, Mexico City, Mexico. Abstract THAB0303.

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部